Please assess the completion status of the following clinical trial:

Trial Title: Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \<29 6/7 and \>24 0/7 weeks gestational age~* Inborn at the participating institution enrolling the patient~* FIO2 \>25% and Intubated with mean airway pressure \> 5 cm H20~* \<8 hours age at randomization~* Signed informed consent from parent(s)~Exclusion Criteria:~* \<500 g birth weight~* \<24 0/7 weeks gestational age (best estimate)~* Prolonged Premature Rupture of membranes \>3 weeks (21 days)~* Apgar score \< 3 at 5 minutes~* Impending death anticipated within the first 3 days of life, moribund~* Severe congenital anomalies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Hours
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
- 2 (Type: EXPERIMENTAL): Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).